Healthcare provider profile · identity verified

Isao Iwata, M.D.

Internal Medicine · PLAINSBORO, NJ · NPI 1295921773

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	433	145
Rosuvastatin Calcium	Rosuvastatin Calcium	258	76
Amlodipine Besylate	Amlodipine Besylate	251	86
Levothyroxine Sodium	Levothyroxine Sodium	144	46
Hydrochlorothiazide	Hydrochlorothiazide	128	38
Losartan Potassium	Losartan Potassium	127	43
Omeprazole	Omeprazole	106	34
Lisinopril	Lisinopril	105	30
Metoprolol Succinate	Metoprolol Succinate	99	36
Metformin Hcl	Metformin Hcl	97	38
Tamsulosin Hcl	Tamsulosin Hcl	82	25
Trazodone Hcl	Trazodone Hcl	81	21
Pantoprazole Sodium	Pantoprazole Sodium	76	22
Escitalopram Oxalate	Escitalopram Oxalate	74	24
Simvastatin	Simvastatin	70	22
Famotidine	Famotidine	64	15
Fluticasone Propionate	Fluticasone Propionate	64	24
Metformin Hcl Er	Metformin Hcl	63	21
Gabapentin	Gabapentin	61	18
Sertraline Hcl	Sertraline Hcl	61	19
Allopurinol	Allopurinol	50	18
Montelukast Sodium	Montelukast Sodium	50	16
Eliquis	Apixaban	46	15
Celecoxib	Celecoxib	44	12
Venlafaxine Hcl Er	Venlafaxine Hcl	41	suppressed
Januvia	Sitagliptin Phosphate	39	15
Memantine Hcl	Memantine Hcl	39	suppressed
Pravastatin Sodium	Pravastatin Sodium	37	13
Clopidogrel	Clopidogrel Bisulfate	33	suppressed
Carvedilol	Carvedilol	32	11
Albuterol Sulfate Hfa	Albuterol Sulfate	31	16
Duloxetine Hcl	Duloxetine Hcl	30	suppressed
Mirtazapine	Mirtazapine	29	suppressed
Alprazolam	Alprazolam	27	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	27	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	27	11
Olmesartan Medoxomil	Olmesartan Medoxomil	27	suppressed
Ezetimibe	Ezetimibe	26	suppressed
Finasteride	Finasteride	26	suppressed
Ramipril	Ramipril	25	suppressed
Alendronate Sodium	Alendronate Sodium	24	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	24	suppressed
Lansoprazole	Lansoprazole	24	suppressed
Telmisartan	Telmisartan	24	suppressed
Rivastigmine	Rivastigmine Tartrate	23	suppressed
Spironolactone	Spironolactone	23	suppressed
Valsartan	Valsartan	23	suppressed
Atenolol	Atenolol	22	suppressed
Furosemide	Furosemide	22	11
Lorazepam	Lorazepam	22	suppressed
Meloxicam	Meloxicam	22	suppressed
Prednisone	Prednisone	22	suppressed
Chlorthalidone	Chlorthalidone	21	suppressed
Glimepiride	Glimepiride	21	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	21	suppressed
Acyclovir	Acyclovir	20	suppressed
Myrbetriq	Mirabegron	20	suppressed
Olanzapine	Olanzapine	20	suppressed
Buspirone Hcl	Buspirone Hcl	19	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	19	suppressed
Trulicity	Dulaglutide	19	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	18	suppressed
Synthroid	Levothyroxine Sodium	18	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	17	suppressed
Bupropion Xl	Bupropion Hcl	17	suppressed
Donepezil Hcl	Donepezil Hcl	17	suppressed
Mometasone Furoate	Mometasone Furoate	16	suppressed
Ventolin Hfa	Albuterol Sulfate	15	suppressed
Breo Ellipta	Fluticasone/Vilanterol	14	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	14	suppressed
Diltiazem 24hr Er (Xr)	Diltiazem Hcl	13	suppressed
Hydrocortisone	Hydrocortisone	13	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Potassium Chloride	Potassium Chloride	13	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	12	suppressed
Irbesartan	Irbesartan	12	suppressed
Oxcarbazepine	Oxcarbazepine	12	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	12	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	12	suppressed
Azithromycin	Azithromycin	11	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	11	suppressed
Humalog Kwikpen U-100	Insulin Lispro	11	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	11	11

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error